accelerated or hyperfractionated radiotherapy for esophageal carcinoma: a meta-analysis of randomized controlled trials

accelerated or hyperfractionated radiotherapy for esophageal carcinoma: a meta-analysis of randomized controlled trials

;Liu YY;Kou CG;Su YY;Zhang YY;You YY;Zhang LL;Wang MH;Fu YL;Ren XJ;Yang YM
jurnal tam 2017 Vol. Volume 10 pp. 2971-2981
175
yy2017oncotargetsaccelerated

Abstract

Yingyu Liu,1 Changgui Kou,1 Yingying Su,1 Yangyu Zhang,1 Yueyue You,1 Lili Zhang,1 Mohan Wang,1 Yingli Fu,1 Xiaojun Ren,2 Yanming Yang2 1Department of Epidemiology and Biostatistics, School of Public Health, Jilin University, 2Department of Radiotherapy, Second Hospital of Jilin University, Changchun, Jilin, People’s Republic of China Objective: The goal of this study was to evaluate the efficacy and safety of modified (accelerated and/or hyperfractionated) radiotherapy in the treatment of esophageal carcinoma, compared with conventional radiotherapy.Methods: Studies published in the PubMed, Cochrane Library, EMBASE, CBM, VIP, CNKI and Wanfang databases in the most recent two decades were searched for use in this meta-analysis. Only randomized controlled trials were included. The heterogeneity analysis and calculation of the pooled odds ratio (OR) were performed using RevMan 5.3 software. The assessment of publication bias and sensitivity analyses was conducted using Stata 13.0 software.Results: Twenty trials with a total of 1,742 Chinese patients who met the inclusion criteria were included. The pooled results showed that modified radiotherapy improved the response rate compared with conventional schedules (OR =3.90, 95% confidence interval [CI]: 2.47–6.16, P<0.001). Favorable results were observed for the 1-year (OR =2.58, 95% CI: 2.05–3.26, P<0.001), 3-year (OR =2.30, 95% CI: 1.83–2.89, P<0.001) and 5-year (OR =2.36, 95% CI: 1.74–3.21, P<0.001) overall survival and for the 1-year (OR =2.46, 95% CI: 1.72–3.51, P<0.001), 3-year (OR =2.08, 95% CI: 1.49–2.90, P<0.001) and 5-year (OR =2.15, 95% CI: 1.38–3.34, P<0.001) overall local control rate in the modified fractionation radiotherapy group. However, the altered radiotherapy increased the risk of acute radiation esophagitis (OR =1.70, 95% CI: 1.27–2.28, P<0.001) and acute radiation tracheitis (OR =1.47, 95% CI: 1.09–1.99, P=0.01). No significant differences in the risk of esophageal perforation (OR =1.30, 95% CI: 0.51–3.32, P=0.58) or esophagorrhagia (OR =0.88, 95% CI: 0.41–1.88, P=0.74) were found between the two groups.Conclusion: Chinese patients with squamous cell esophagus carcinomas gained a significant benefit in terms of the response rate, survival and local control rates from the modified fractionation radiotherapy, but also had an increased risk of acute radiation reactions. Otherwise, there was no observed statistically significant difference in terms of early adverse reactions. Keywords: esophageal carcinoma, radiotherapy, fractionation, meta-analysis

Citation

ID: 245682
Ref Key: yy2017oncotargetsaccelerated
Use this key to autocite in SciMatic or Thesis Manager

References

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
245682
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
5/5
Creates 1,000,000 NFT tokens for this article
Token Features:
  • ERC-1155 Standard NFT
  • 1 Million Supply per Article
  • Transferable via MetaMask
  • Permanent Blockchain Record
Blockchain QR Code
Scan with Saymatik Web3.0 Wallet

Saymatik Web3.0 Wallet